Therefore, in conclusion, these data are immature; however, at this stage, we can hypothesize that LIPI could be a prognostic predictor of the success of chemoimmunotherapy for patients with advanced NSCLC with a PD-L1 TPS < 50%, but whether LIPI could be a real prognostic predictor for the success of chemoimmunotherapy for patients with advanced NSCLC remains controversial. This evidence concerns the gene CD274 and non-small cell lung carcinoma.